NEW YORK, July 1, 2019 /PRNewswire/ -- Renalytix AI
plc (LON: RENX), a developer of artificial intelligence-enabled
clinical diagnostics for kidney disease, announced today that the
American Medical Association (AMA) has granted a CPT®
Proprietary Laboratory Analyses (PLA) Code for its
lead product, KidneyIntelX™. The new code, 0105U, has
been approved and published by the AMA CPT Editorial Panel, and is
scheduled to become effective on October 1,
2019.
A payment rate for the new code will be established for Medicare
patients through the 2019 Clinical Lab Fee Schedule (CLFS) Annual
Public Meeting process. Renayltix AI will shortly provide comments
and a recommendation on the appropriate basis for establishing a
national Medicare price for this new CPT code expected to be
effective January 1, 2020.
"This is an important step as we prepare for
KidneyIntelX's scaled roll-out in the United States," said Michael J. Donovan, Ph.D., MD, Chief Medical
Officer, RenalytixAI. "A CPT Code is instrumental in obtaining
insurance coverage and reimbursement, and will increase access to
KidneyIntelX testing results for patients with chronic
kidney disease."
The CPT terminology is the most widely accepted medical
nomenclature used across the United
States to report medical, surgical, radiology, laboratory,
anesthesiology, genomic sequencing, evaluation and management
services under public and private health insurance programs.
Recently added to the CPT Code set, PLA Codes are
alpha-numeric CPT codes with a corresponding descriptor for labs or
manufacturers that want to identify their test more
specifically.
KidneyIntelX is designed to improve
identification and clinical management of patients with Type 2
diabetes with fast-progressing kidney disease in an effort to
curtail the estimated $114 billion annual cost1 of
chronic and end-stage kidney disease to the United States healthcare system.
KidneyIntelX uses machine learning algorithms to assess a
combination of predictive blood-based biomarkers, including sTNFR1,
sTNFR2 and KIM1, and features from a patient's electronic health
record.
In a recent study published April 1,
2019, and publicly announced by RenalytixAI on the same
date, algorithms used at the core of KidneyIntelX
significantly increased the ability to positively predict which
patients went on to experience rapid kidney function decline
(RKFD). For this group of patients experiencing RKFD and at
significant risk of progressing to end-stage kidney disease and
dialysis, there are several clinical management strategies and
proven therapeutic options available. One of the greatest drivers
of health care cost today is RKFD patients who are not diagnosed in
time and face unplanned kidney failure through emergency room
'crash' dialysis.
About Kidney Disease
Kidney disease is now
recognized as a public health epidemic affecting over 850 million
people globally. In the United
States alone, over 40 million people are classified as
having chronic kidney disease, with nearly 50 percent of
individuals with advanced (Stage IV) disease unaware of the
severity of their reduced kidney function. As a result, many
patients progress to kidney failure in an unplanned manner, ending
up having dialysis in the emergency room without ever seeing a
clinical specialist, such as a nephrologist. Every day 13 patients
die in the United States while
waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of
artificial intelligence-enabled clinical solutions for kidney
disease, one of the most common and costly chronic medical
conditions globally. The Company's solutions are being designed to
make significant improvements in kidney disease diagnosis and
prognosis, clinical care, patient stratification for drug clinical
trials, and drug target discovery. For more information, visit
renalytixai.com.
1United States Renal Data System -
https://www.usrds.org/adrhighlights.aspx.
View original
content:http://www.prnewswire.com/news-releases/us-cpt-code-granted-for-kidneyintelx-300878339.html
SOURCE RenalytixAI